EUDRAC has been acquired by The QbD Group

Wilrijk, Belgium & Oxfordshire, UK. – The QbD Group, a privately held company offering comprehensive support to life science companies throughout the entire product lifecycle, today announced the acquisition of EUDRAC Ltd., a specialist regulatory and pharmacovigilance consultancy.

EUDRAC Ltd. provides a bespoke consultancy service throughout product development, regulatory approval, market launch, and into life cycle management. Their success is built upon strong relationships with EMA and MHRA and experience across a wide range of therapeutic areas, pharmaceutical forms, and in-depth knowledge of legislation and guidance.

Joining the QbD Group will allow EUDRAC Ltd. access to a broader client base and the infrastructure necessary to ensure continued growth. EUDRAC Ltd. will be renamed QbD Ltd.

In turn, this acquisition will expand the QbD Group’s regulatory affairs division to better serve its pharmaceutical customers, including those developing advanced therapy medicinal products (ATMPs).

Carole Pugh, Managing Director of EUDRAC commented: “We’re delighted to bring our expertise into the QbD group. This is the right time for us to make this step and will allow us to benefit from the synergies the acquisition will bring. In addition to bringing opportunities for business growth, it will give our team of experts opportunities to broaden their knowledge and skills.”

Bart Van Acker, Founder and CEO of QbD said: “The QbD Group is continuously expanding our already broad ecosystem through strategic alliances and acquisitions. The addition of EUDRAC Ltd. takes us yet another step closer to our QbDream of offering a comprehensive range of skills and expertise to support product development throughout the life sciences.”

See here for full information:  https://qbdgroup.com/en/news/eudrac/